AXERT 12.5mg time vs Intensity Migraine Study (AIMS): an open-label multicenter trial to evaluate the efficacy of almotriptan malate (AXERT12.5 milligram intervention at onset of migraine pain.

Trial Profile

AXERT 12.5mg time vs Intensity Migraine Study (AIMS): an open-label multicenter trial to evaluate the efficacy of almotriptan malate (AXERT12.5 milligram intervention at onset of migraine pain.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2010

At a glance

  • Drugs Almotriptan (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms AIMS
  • Most Recent Events

    • 05 May 2009 Actual patient number (1450) added as reported by ClinicalTrials.gov.
    • 19 Oct 2007 Status changed from in progress to completed.
    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top